Lindexer
The computed 12-month bankruptcy probability of Lindexer is 1.6% (moderate). The 2024 annual accounts show negative equity (€-89k) and a net result of €-92k. Its solvency ranks better than 15% of 230 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-89k |
| Net result | €-92k |
| Better than sector | 15% |
| Active | 2 yrs |
Strong profile, led by profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -28.1% | 47.1% | |
| Net result | €-92k | €5k | |
| Equity | €-89k | €26k | |
| Gross operating margin | €-59k | €17k | |
| Staff costs | €259 | €35k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €-59k |
| Net profit | €-92k |
| Cash flow | €-78k |
| Staff costs | €259 |
| Income taxes | - |
| Dividends | - |
| Total assets | €315k |
| Equity | €-89k |
| Debt | €404k |
| of which ≤ 1y | €44k |
| of which > 1y | €360k |
| Working capital | €103k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 3.33 |
| Quick ratio | 3.33 |
| Working capital ratio | 32.6% |
| Solvency | -28.1% |
| Debt / equity | -4.56 |
| Long-term debt ratio | -4.06 |
| Interest coverage | -3.09 |
| Gross margin | - |
| Net margin | - |
| ROA | -29.1% |
| ROE | 103.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €315k |
| Fixed assets | 21/28 | €168k |
| Intangible fixed assets | 21 | €168k |
| Current assets | 29/58 | €147k |
| Amounts receivable within one year | 40/41 | €3k |
| Cash & bank | 54/58 | €144k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €315k |
| Equity | 10/15 | €-89k |
| Contributions / capital | 10/11 | €3k |
| Accumulated profits (losses) | 14 | €-92k |
| Amounts payable | 17/49 | €404k |
| Amounts payable after one year | 17 | €360k |
| Amounts payable within one year | 42/48 | €44k |
| Trade debts payable within one year | 44 | €4k |
| Income statement | ||
| Gross operating margin | 9900 | €-59k |
| Operating result | 9901 | €-73k |
| Financial charges | 65 | €19k |
| Result before taxes | 9903 | €-92k |
| Net result for the period | 9904 | €-92k |
| Result to be appropriated | 9905 | €-92k |
Former directors (1)
-
BV Eelen Clinical ConsultingLegal entityDirector· perm. rep.: EELEN JanState Gazette act 25153858 (05-12-2025)Former- → 07-10-2025
| NACE primary | 58290 |
| Legal form | Private limited company(610) |
| Incorporation | 05-10-2023 |
| Status | Active |
| Postal code | 2610 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11462A0291/00K007 | Flanders | 757 m² | 1 · 343 m² | 10.2 m · 1 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
05-12-2025 1 director appointed, 1 resigning
- BV Hugin Mugin research, Bestuurder
- EELEN Jan, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "EELEN Jan",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "BV Eelen Clinical Consulting",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2025-10-07",
"evidence_quote": "De algemene vergadering neemt kennis van het ontslag van de BV Eelen Clinical Consulting, vertegenwoordigd door haar vaste vertegenwoordiger Dhr. EELEN Jan, ontvangen per mail en per aangetekend schrijven dd. 7 oktober 2025 als bestuurder, en bevestigt met deze het ontslag met onmiddellijke ingang v"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "BV Hugin Mugin research",
"address": null,
"birth_date": null
},
"evidence_quote": "Onderwerp akte: Ontslag BV Eelen Clinical Consulting als bestuurder en benoeming BV Hugin Mugin research als algemeen bestuurder"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1000.821.155",
"name_full": "LINDEXER",
"legal_form": "BV"
}
}09-10-2023 Incorporation of a new BV
Technical details
{
"kind": "oprichting",
"seat": "Koning Leopoldstraat 18, 2610 Antwerpen (Wilrijk)",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1974-01-08",
"name": "PERSY Veerle Paula Christel",
"niss": null,
"address": "Koning Leopoldstraat 18, 2610 Antwerpen (Wilrijk)"
},
"share_class": "A",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 1503,
"holder_person_name": "PERSY Veerle Paula Christel",
"is_subscriber_only": false,
"n_shares_subscribed": 501,
"amount_subscribed_eur": 1503,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1977-06-12",
"name": "EELEN Jan August Elisabeth",
"niss": null,
"address": "Posthoornstraat 14, 2500 Lier"
},
"share_class": "A",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 1500,
"holder_person_name": "EELEN Jan August Elisabeth",
"is_subscriber_only": false,
"n_shares_subscribed": 500,
"amount_subscribed_eur": 1500,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 3003,
"subject_company": {
"kbo": "1000.821.155",
"name_full": "Lindexer",
"legal_form": "BV"
},
"initial_directors": [],
"incorporation_date": "2023-10-04",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Lindexer |